Essentialis

Essentialis is a pharmaceutical company focused on the development of breakthrough medicines for the treatment of cardiovascular and metabolic diseases.

The company's portfolio of products is targeted at the ATP-sensitive potassium channel, a metabolically-regulated membrane protein whose modulation has the potential to impact a wide range of cardiovascular and metabolic diseases.

The company is currently planning to advance it's lead product, DCCR, into Phase III trials in patients with very high triglycerides.